Sensyne Health

Sensyne Health is a Clinical AI company working in partnership with the NHS

Our mission is to improve health and create wealth for all through the ethical application of clinical artificial intelligence and the creation of a trusted data community between patients, clinicians, healthcare providers and life science companies that is transparent, fair and effective.

Sensyne Health is a clinical artificial intelligence company operating a unique business model. We are a for-profit plc making a positive social impact, sharing the financial returns we make with the NHS via equity and a share of revenues. The company applies Clinical AI in two markets:

- **Healthcare industry:** we supply advanced patient monitoring software to healthcare providers that improve patient outcomes and reduce costs
- **Life science industry:** we undertake research on behalf of pharmaceutical companies using clinical AI to analyse anonymised patient records to accelerate the development of new medicines

Two divisions

Discovery Sciences

Connecting the life sciences industry with the NHS

- Curate ethically sourced anonymised electronic patient data from Sensyne's unique partnership with the NHS
- Apply clinical AI to analyse the data and answer clinically relevant questions and generate new discovery hypotheses
- The approach creates a docking station between the NHS and the pharmaceutical industry, creating scientific value and providing a financial return to the NHS

Software Products

Connecting clinicians with patients

- Develops digital health products to assist clinicians with decision-making and improve patient care
- Software products span a variety of applications including prescribed digital therapeutics, remote care and advanced hospital system digital monitoring
- These digital products generate large databases of phenotypic data enabling discovery research and improved patient care, contact, communications and outcomes

Products

CVm-Health™
Coronavirus self-monitoring

GDm-Health™
Monitoring and management of diabetes in pregnancy

BPm-Health™
Self-monitoring of blood pressure during pregnancy

DBm-Health™
Recording data for patients with or at risk of diabetess

SEND™
Vital sign observations

EDGE™
Management of COPD

CleanSpace™
Air quality research application

Support-HF™
Management of heart failure

Operational highlights 2019-20

Launched coronavirus **CVm-Health** 'Good Neighbour' app in the UK and in the US with support from **Microsoft** and **Cognizant**

Launched new **BPm-Health** remote monitoring system in the UK for the management of blood pressure in pregnancy in response to the coronavirus pandemic

Launched **DBm-Health** app for recording data for patients with or at risk of diabetes in response to the coronavirus pandemic

Sensyne supplied **GDm-Health**, **CVm-Health** and **BPm-Health** products for free to the NHS during the coronaviruspandemic

Signed first major pharmaceutical collaboration agreement for **£5 million** with **Bayer** to accelerate the development of new treatments for cardiovascular disease using Clinical AI

Later entered into an additional partnership around Bayer's new **UK AI 'LifeHub'** for data-driven drug discovery, disease detection and diagnosis

Signed research collaboration with **Roche** to apply AI for clinical trial design

Signed collaboration with **Alexion** to study the prevalence and outcomes of patients in select disease areas

Signed agreements with **Cognizant** and **Agorai** for the launch and sale of digital health software products in the US

Entered into a formal research agreement with the **UK MHRA** to contribute to the development of methods to validate software algorithms used in digital health

Entered into the **LAB10x** partnership with **Evotec**, **Oxford University Innovation**, **Oxford Sciences Innovation** and the **University of Oxford** to accelerate the commercialisation of next-gen digital therapeutics and data-driven drug discovery

Became a **Microsoft** strategic partner to develop **Health Cloud** capabilities

Announced the development of the **SENSE** algorithm engine in partnership with **Microsoft** – a real-time decision support service for clinicians across multiple conditions

Signed agreement with **Chelsea & Westminster Hospital** for the **SENSE** generated algorithm to be used for coronavirus

www.sensynehealth.com

Schrödinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE

Financial highlights

April 2020 Trading Update (unaudited):
- Revenues of £2.1m (2019: £0.1m)
- Cash £31.6m (2019: £49.3m)

April 2020 Trading Update (unaudited):
- Market share of 47% across NHS in England for diabetes in pregnancy product GDm-Health
- 3 new remote monitoring products launched since 20 April 2020
- 3 agreements signed with pharmaceutical customers since July 2019

Leadership

Sir Bruce Keogh KBE FRCS FRCP
Non-executive Chairman

Rt. Hon. Lord Drayson PhD FREng
Chief Executive Officer

Pharmaceutical customers

Roche   ALEXION   BAYER

Health system partners

NHS South Warwickshire NHS Foundation Trust
NHS Chelsea and Westminster Hospital NHS Foundation Trust
NHS Oxford University Hospitals NHS Foundation Trust
Jefferson Philadelphia University + Thomas Jefferson University

Research partner

UNIVERSITY OF OXFORD

Technology partner

Microsoft

US Sales & Marketing Partner

Cognizant

Top Shareholders

Drayson Family	**29.1%**
Acacia Research Corporation	**11.8%**
Lansdowne Partners	**10.43%**
Baillie Gifford & Co	**5.60%**
Gatemore Capital Mgt	**5.41%**
Oxford University Hospitals NHS Foundation Trust	**4.39%**